StockNews.com cut shares of SCYNEXIS (NASDAQ:SCYX – Free Report) from a hold rating to a sell rating in a report published on Saturday morning.
SCYNEXIS Stock Performance
SCYNEXIS stock opened at $1.04 on Friday. The firm’s 50 day simple moving average is $1.06 and its 200 day simple moving average is $1.24. The firm has a market capitalization of $40.54 million, a PE ratio of -1.41 and a beta of 1.67. SCYNEXIS has a 1-year low of $0.82 and a 1-year high of $3.07.
SCYNEXIS (NASDAQ:SCYX – Get Free Report) last posted its earnings results on Wednesday, March 12th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.13. The business had revenue of $0.98 million for the quarter. SCYNEXIS had a negative net margin of 425.41% and a negative return on equity of 66.21%.
Institutional Trading of SCYNEXIS
About SCYNEXIS
SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.
Read More
- Five stocks we like better than SCYNEXIS
- 3 Warren Buffett Stocks to Buy Now
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
- How to Choose Top Rated Stocks
- Alphabet Stock Becomes a Low-Risk, High-Reward Play
- 5 discounted opportunities for dividend growth investors
- Affirm Stock: Should You Buy the Dip After Walmart Setback?
Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.
